Phase 1 Study Results of JNJ-78278343 (pasritamig) in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: 177Lu-NYM032 Shows Efficacy In mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1/by MaxPRESERVE-006 Phase 1 Trial Results: Gotistobart (BNT316/ONC-392) and 177Lu Combination Shows Promise for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxVIOLET Phase 1/2 Trial Final Results: 161Tb-PSMA-I&T Shows Promising Results
/0 Comments/in Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Trial of Novel Radioligand Therapy 177Lu-JH020002 Shows Promise
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxPhase 1/2 Results for MHB088C Antibody-Drug Conjugate for mCRCP
/0 Comments/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxMevrometostat Update: Phase 2 Clinical Trial Keeps Showing Promising Results
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxCOMRADE Phase 2 Trial Initial Results: Combination of Olaparib and Radium-223 Shows Promise in Extending Progression-Free Survival
/0 Comments/in Clinical Trial, Metastatic, Phase 2/by MaxTALAPRO-2 Trial: Final OS Analisys Confirms Talazoparib + Enzalutamide Effectiveness in mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare antibody-drug conjugate apalutamide artificial intelligence ASCO 2025 ATM bispecific antibody bone metastases bone metastasis BRCA cancer immunotherapy cancer treatment castration-resistant prostate cancer CDK12 clinical trial clinical trials crispr CYP11A1 inhibitor darolutamide drug repurposing drug resistance enzalutamide HRR immune checkpoint inhibitors immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA nanotechnology olaparib oncolytic virus personalized medicine prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data theranostics
Latest Posts
- UPDATE: OncoACP3 Moving to Phase 1 Trial as Therapeutic Agent June 12, 2025
- Sn-117m-DTPA Emerges as Theranostic: Phase 1/2 Trials June 11, 2025
- Newsletter 23/2025 June 8, 2025
- Protein Design Leaps Forward Thanks to AI June 5, 2025